27.96 USD
▲+0.41+1.49%
盘后 27.00 -3.43%
2026-11-19
市值
$2.15B
市盈率
—
EPS
-4.27
股息率
—
52 周区间
22.33 – 45.14
成交量
751.76K
Beta
1.03
目标价
61.57
52W 低 22.3352W 高 45.14
价格走势
公司简介
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,...
关联新闻
- Celldex ends eczema drug development after mid-stage trial failure
Celldex Therapeutics said on Thursday it would stop developing its experimental drug for eczema after the treatment failed to meet the main and key secondary goals of a mid-stage study.